Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte F M Slangen

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Journal of the National Cancer Institute|November 23, 2024
High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriersIris A S Stroot, Joost Bart, Harry Hollema, et al.
BMC Cancer|August 20, 2015
Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre studyMarline G Harmsen, Marieke Arts-de Jong, Nicoline Hoogerbrugge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of <i>BRCA1/2</i> Pathogenic Variants: Prevalence and Clinical FactorsIris A S Stroot, Jan Brouwer, Joost Bart, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 8, 2022
Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factorsMajke H D van Bommel, Miranda P Steenbeek, Joanna IntHout, et al.
JAMA Oncology|June 3, 2021
Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled TrialMiranda P Steenbeek, Marline G Harmsen, Nicoline Hoogerbrugge, et al.
Maturitas|February 23, 2026
Development of cardiovascular risk factors in women with a BRCA1/2 pathogenic variant within five years after tubo-ovarian cancer risk reduction in the TUBA studyTamar A Gootzen, Marleen M H J van Gelder, Rosella P M G Hermens, et al.
Maturitas|April 22, 2025
No increased arterial stiffness after premenopausal risk-reducing salpingo-oophorectomy (RRSO)Maarten J Beekman, Lara Terra, Jeanine E Roeters van Lennep, et al.
Gynecologic Oncology|May 25, 2024
Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriersIris A S Stroot, Joost Bart, Harry Hollema, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|January 17, 2025
Salpingectomy With Delayed Oophorectomy Versus Salpingo-Oophorectomy in BRCA1/2 Carriers: Three-Year Outcomes of a Prospective Preference TrialMajke H D Van Bommel, Miranda P Steenbeek, Joanna Inthout, et al.
Maturitas|February 22, 2026
Long-term outcomes of surgical menopause after risk-reducing salpingo-oophorectomy: results of the HARMOny studyMaarten J Beekman, Lara Terra, Eveline M A Bleiker, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of the National Cancer Institute|November 23, 2024
High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriersIris A S Stroot, Joost Bart, Harry Hollema, et al.
BMC Cancer|August 20, 2015
Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre studyMarline G Harmsen, Marieke Arts-de Jong, Nicoline Hoogerbrugge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of <i>BRCA1/2</i> Pathogenic Variants: Prevalence and Clinical FactorsIris A S Stroot, Jan Brouwer, Joost Bart, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 8, 2022
Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factorsMajke H D van Bommel, Miranda P Steenbeek, Joanna IntHout, et al.
JAMA Oncology|June 3, 2021
Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled TrialMiranda P Steenbeek, Marline G Harmsen, Nicoline Hoogerbrugge, et al.
Maturitas|February 23, 2026
Development of cardiovascular risk factors in women with a BRCA1/2 pathogenic variant within five years after tubo-ovarian cancer risk reduction in the TUBA studyTamar A Gootzen, Marleen M H J van Gelder, Rosella P M G Hermens, et al.
Maturitas|April 22, 2025
No increased arterial stiffness after premenopausal risk-reducing salpingo-oophorectomy (RRSO)Maarten J Beekman, Lara Terra, Jeanine E Roeters van Lennep, et al.
Gynecologic Oncology|May 25, 2024
Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriersIris A S Stroot, Joost Bart, Harry Hollema, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|January 17, 2025
Salpingectomy With Delayed Oophorectomy Versus Salpingo-Oophorectomy in BRCA1/2 Carriers: Three-Year Outcomes of a Prospective Preference TrialMajke H D Van Bommel, Miranda P Steenbeek, Joanna Inthout, et al.
Maturitas|February 22, 2026
Long-term outcomes of surgical menopause after risk-reducing salpingo-oophorectomy: results of the HARMOny studyMaarten J Beekman, Lara Terra, Eveline M A Bleiker, et al.
Pageof 5